| Literature DB >> 33227712 |
Yaqiong Zhan1, Lushun Jiang1, Xuehang Jin1, Shuaibing Ying1, Zhe Wu1, Li Wang2, Wei Yu1, Jiepeng Tong1, Li Zhang1, Yan Lou1, Yunqing Qiu3.
Abstract
RRM2, the small subunit of ribonucleotide reductase, is identified as a tumor promotor and therapeutic target. It is common to see the overexpression of RRM2 in chemo-resistant cancer cells and patients. RRM2 mediates the resistance of many chemotherapeutic drugs and could become the predictor for chemosensitivity and prognosis. Therefore, inhibition of RRM2 may be an effective means to enhance the anticancer activity of chemotherapy. This review tries to discuss the mechanisms of RRM2 overexpression and the role of RRM2 in resistance to chemotherapy. Additionally, we compile the studies on small interfering RNA targets RRM2, RRM2 inhibitors, kinase inhibitors, and other ways that could overcome the resistance of chemotherapy or exert synergistic anticancer activity with chemotherapy through the expression inhibition or the enzyme inactivation of RRM2.Entities:
Keywords: Chemoresistance; Chemotherapy; Kinase inhibitors; RRM2 inhibitors; Ribonucleotide reductase subunit M2; Small interfering RNA
Mesh：
Substances：
Year: 2020 PMID： 33227712 DOI： 10.1016/j.biopha.2020.110996
Source DB: PubMed Journal: Biomed Pharmacother ISSN： 0753-3322 Impact factor: 6.529